The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|July 1, 2007
Applied Clinical Trials Supplements
- Supplements-11-06-2007
- Volume 0
- Issue 0
eShowcase: iTrial EDC
Latest iTrial EDC Includes New PDF Generation Tool to Improve Audit Trail Function
Advertisement
Latest iTrial EDC Includes New PDF Generation Tool to Improve Audit Trail Function
Almac Clinical Technologies' (Yardley, PA) latest iTrial EDC release features the newest version of the company's PDF Generation Tool, which is consistent with current FDA eSubmission guidance.
This tool allows sponsors to generate PDFs of their electronic case report forms (eCRFs) for site archival purposes, as well as to complement data submitted for a New Drug Application (NDA).
iTrial EDC allows sponsors to view all data captured with a full audit trail and also to select and view the audit trail for only the data that has changed. The tool includes hyperlink capabilities, which allow users to link to altered fields and associated comments as well as clinical queries.
FDA recently discussed the value of audit trails within eCRFs submitted in PDF format, which sponsors do not typically include.
Almac Clinical Technologies, (267) 685-4284,
Articles in this issue
about 19 years ago
eShowcase: EDC 2.0over 19 years ago
EDC Progress Steady for Europe and Asiaover 19 years ago
Impact of EDC on Clinical Staff Rolesover 19 years ago
The Role of EDC in Adaptive Clinical Trialsabout 20 years ago
eShowcase: LabPas CT 2.5Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5